- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Beta Drugs Limited — Board Meeting, 06-11-2025: Outcome of Board Meeting
06-11-2025 | 03:10 pm
06-11-2025 | 03:10 pm
Beta Drugs' board approved H1 FY26 results. Consolidated revenue grew 13% to ₹203.6 Cr, with EBITDA up 17% to ₹47 Cr. Adjusted net profit rose 18% to ₹28.71 Cr. Strategic highlights include oncology facility acquisition and major global product filings.
No comments yet. Be the first to comment!